Metacam
Generic Name
Meloxicam
Indications/Uses
Metacam is indicated for the management of fever and pain and inflammation caused by progressive osteoarthritis, disco-spondylosis, arthropathy and soft tissue injuries in dogs and cats. It is available in both injectable and oral forms in dogs. Metacam belongs to the class of non-steroidal anti-inflammatory drugs (NSAID), which eases pain by hindering the secretion of prostaglandins. It brings fast relief to both pain and inflammation and is relatively free from the many adverse side effects of conventional NSAIDs, making it a popular drug among pets.
Precautions
Metacam is best avoided in animals with a known history of hypersensitivity to these drugs and those with stomach ulcers and Von Willebrand’s disease. It is not advisable to administer this medication in pets with heart, kidney or liver disease or in pregnant or lactating animals. Animals suffering from dehydration, inflammatory bowel disease or those under diuretics also should not be treated with Metacam. It should never be given along with other NSAIDs such as aspirin or steroids as it might result in stomach ulcers and other complications. Pets being treated with metacam should be regularly monitored for kidney and liver functions.
Side Effects
Though side effects are rare if administered on prescription, in some cases, side effects such as depression, loss of appetite, jaundice, vomiting, pale gums, fast breathing etc are noticed in some animals while being treated with Metacam. Some unforeseen side effects like intestinal bleeding, papillary necrosis and peritonitis could be fatal, if ignored.
Dosage Information
Normally the initial dose of Metacam in dogs is 0.1mg/lb as a single initial dose and later on it could be reduced to a single daily dose of 0.05mg/lb as a maintenance dose. The honey flavored oral suspension could be given with food or separately. In cats, Metacam is labeled for a subcutaneous injection at a dose of 0.14 mg/lb in managing post surgical pain or inflammation.
Brand Names
Metacam (Boehringer Ingelheim)